Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Taylor Tang

Surgery Orange, CA Medical Doctor

NPI 1851611354 CMS profile 1213308

1310 W Stewart Dr, Suite 503, Orange, CA 92868

Open in the dashboard

General payments

$22,881

309 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Taylor Tang of Orange, CA is reported in the CMS Open Payments database as having received $22,881 across 309 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,990 60
2024 General $6,396 76
2023 General $3,340 54
2022 General $2,987 41
2021 General $1,225 19
2020 General $2,301 19
2019 General $2,643 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Taylor Tang
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Taylor Tang were reported at $3,990. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Taylor Tang Surgery median Middle half National median
2019 $2,643 $253 $82–$1,521 $163
2020 $2,301 $131 $40–$706 $114
2021 $1,225 $168 $50–$904 $132
2022 $2,987 $224 $76–$1,218 $149
2023 $3,340 $253 $82–$1,255 $160
2024 $6,396 $279 $90–$1,381 $164
2025 $3,990 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $6,306 68 payments
  2. Atricure, Inc. $4,533 71 payments
  3. Abiomed $3,523 46 payments
  4. Abbott Laboratories $2,131 28 payments
  5. Medtronic, Inc. $1,167 17 payments
  6. Baxter Healthcare $852 11 payments
  7. W. L. Gore & Associates, Inc. $659 5 payments
  8. AngioDynamics, Inc. $607 6 payments
  9. Becton, Dickinson and Company $500 1 payment
  10. Kestra Medical Technology Services, Inc. $498 9 payments
  11. Other $2,107 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,995 300 payments
  2. Consulting Fee $2,150 2 payments
  3. Honoraria $1,200 1 payment
  4. Travel and Lodging $536 6 payments
Products named General payments · program years 2019–2025
  1. Impella $2,475 30 payments
  2. ATRICLIP LAA EXCLUSION SYSTEM $2,328 32 payments
  3. SYNERGY ABLATION SYSTEM $1,546 26 payments
  4. MITRIS RESILIA Mitral Valve $946 11 payments
  5. ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2) $759 14 payments
  6. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $722 12 payments
  7. INSPIRIS RESILIA AORTIC VALVE $637 8 payments
  8. AtriCure cryoICE cryoSPHERE Cryoablation System $621 9 payments
  9. ATRICURE ATRICLIP LAA EXCLUSION $555 7 payments
  10. EPIC $547 7 payments
  11. Other $9,894 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Cardiac Surgery: 68

Drug cost

$23

Median for Cardiac Surgery: $445

Branded share of claims

0%

Median for Cardiac Surgery: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoprolol Tartrate Generic 12 $23

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 411 Part D prescribers listed as Cardiac Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$85,761

Medicare's payments for the services billed

Medicare patients

124

Average age 78

Services billed

306

28 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 67%
Atrial fibrillation 59%
Arthritis 49%
Diabetes 45%
Chronic kidney disease 40%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

309 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record